Hypertrophic Obstructive Cardiomyopathy: Septal Ablation With Overlapping Sirolimus-Eluting and Covered Stents After Failed Alcoholization and Concomitant Coronary Artery Disease
A 61-year-old man with exertional dyspnea was diagnosed with hypertrophic obstructive cardiomyopathy. The echocardiogram demonstrated an interventricular septum with a thickness of 18 mm, marked systolic anterior motion, and mitral regurgitation grade 3. The left ventricular outflow tract (LVOT) gradient was 100 mm Hg. The patient was treated with percutaneous transluminal septal myocardial alcohol ablation, resulting in a residual LVOT gradient of 20 mm Hg. Mild coronary artery disease of the proximal left anterior descending coronary artery (LAD) and the first diagonal branch (D1) (40% diameter stenosis by quantitative coronary angiography) was left untreated.
The patient remained asymptomatic for 6 months and then again had development of exertional dyspnea. The echocardiogram revealed relapse of the LVOT gradient (80 mm Hg). Repeat percutaneous transluminal septal myocardial alcohol ablation was planned. The invasive LVOT gradient was 77 mm Hg. Coronary angiography demonstrated progression of the disease of both lesions in the LAD and D1 (70% by quantitative coronary angiography). Because of the concomitant coronary artery disease, the treatment plan was changed. The LAD and the D1 were treated with sirolimus-eluting stent implantation (Figure 1A). Instead of injecting ethanol, a polytetrafluoroethylene-covered stent was implanted within the borders of the sirolimus-eluting stent over the ostium of the septal artery (Figure 1B). The procedure resulted in occlusion of the septal branch and immediate reduction of the LVOT gradient to 12 mm Hg (Figure 1C). The creatine kinase level rose to 789 IU/L. At 12 months’ follow-up, the patient remained asymptomatic. Repeat angiography revealed no restenosis (Figure 1D), and intravascular ultrasound showed complete absence of neointima formation (Figure 1F and 1G). Furthermore, no signs of septal collateralization through the right coronary artery were noted (Figure 1E). There was no rest gradient. Multislice computed tomography imaging demonstrated good stent patency (Figure 2), and magnetic resonance imaging with gadolinium demonstrated the region of the infarcted interventricular septum (Figure 3). Septal reperfusion through collaterals leading to treatment failure after occlusion with covered stents has been previously reported.1,2 In our case, this probably was prevented by myocardial fibrosis and destruction of the microcirculation after the initial alcoholization.
Disclosures
None.
References
1.
Fifer MA, Yoerger DM, Picard MH, Vlahakes GJ, Palacios IF. Covered stent septal ablation for hypertrophic obstructive cardiomyopathy: initial success but ultimate failure resulting from collateral formation. Circulation. 2003; 107: 3248–3249.
2.
Anzuini A, Uretsky BF. Covered stent septal ablation for hypertrophic obstruction cardiomyopathy. Circulation. 2004; 109: e6.
Information & Authors
Information
Published In
Copyright
© 2006.
History
Published online: 24 October 2006
Published in print: 24 October 2006
Subjects
Authors
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
- Effective treatment of hypertrophic cardiomyopathy with left ventricular outflow tract obstruction using a covered stent, BMJ Case Reports, 15, 12, (e250929), (2022).https://doi.org/10.1136/bcr-2022-250929
- Unstable angina complicated with dynamic left ventricular outflow tract obstruction, Journal of Cardiology Cases, 23, 4, (181-188), (2021).https://doi.org/10.1016/j.jccase.2021.01.013
- Very long-term outcome of coronary covered stents: a report from the SCAAR registry, EuroIntervention, 14, 16, (1660-1667), (2019).https://doi.org/10.4244/EIJ-D-18-00855
- Contemporary techniques for catheter-based intervention for hypertrophic obstructive cardiomyopathy, EuroIntervention, 12, X, (X44-X47), (2016).https://doi.org/10.4244/EIJV12SXA9
- Aortic Valve Valvuloplasty, Percutaneous Treatment of Cardiovascular Diseases in Women, (103-110), (2016).https://doi.org/10.1007/978-3-319-39611-8_7
- Patterns of Left Ventricular Remodeling in Aortic Stenosis: Therapeutic Implications, Current Treatment Options in Cardiovascular Medicine, 17, 7, (2015).https://doi.org/10.1007/s11936-015-0391-0
- Low Gradient Aortic Stenosis, Current Treatment Options in Cardiovascular Medicine, 17, 5, (2015).https://doi.org/10.1007/s11936-015-0378-x
- Assessment of low-flow, low-gradient aortic stenosis: multimodality imaging is the key to success, EuroIntervention, 10, U, (U52-U60), (2014).https://doi.org/10.4244/EIJV10SUA8
- Management of aortic valve disease in the presence of left ventricular dysfunction, Expert Review of Cardiovascular Therapy, 8, 2, (259-268), (2014).https://doi.org/10.1586/erc.09.171
- Ejection Fraction/Velocity Ratio Identifies Prosthesis-Patient Mismatches in Patients With Aortic Bioprosthetic Valves and Left Ventricular Dysfunction, Journal of Ultrasound in Medicine, 28, 9, (1167-1174), (2009).https://doi.org/10.7863/jum.2009.28.9.1167
- See more
Loading...
View Options
Get Access
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
Purchase this article to access the full text.
eLetters(0)
eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.
Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.